Literature DB >> 30511248

Treatment with a polymyxin B filter to capture endotoxin in sepsis patients: is there a signal for therapeutic efficacy?

Peter Pickkers1,2, James A Russell3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30511248     DOI： 10.1007/s00134-018-5481-5

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  8 in total

Review 1.  Blood purification and mortality in sepsis: a meta-analysis of randomized trials.

Authors:  Feihu Zhou; Zhiyong Peng; Raghavan Murugan; John A Kellum
Journal:  Crit Care Med       Date:  2013-09       Impact factor: 7.598

2.  Polymyxin B hemoperfusion and mortality in abdominal septic shock.

Authors:  Jean-Louis Vincent
Journal:  JAMA       Date:  2009-11-11       Impact factor: 56.272

3.  Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock.

Authors:  S M Opal; P J Scannon; J L Vincent; M White; S F Carroll; J E Palardy; N A Parejo; J P Pribble; J H Lemke
Journal:  J Infect Dis       Date:  1999-11       Impact factor: 5.226

4.  Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial.

Authors:  Dinna N Cruz; Massimo Antonelli; Roberto Fumagalli; Francesca Foltran; Nicola Brienza; Abele Donati; Vincenzo Malcangi; Flavia Petrini; Giada Volta; Franco M Bobbio Pallavicini; Federica Rottoli; Francesco Giunta; Claudio Ronco
Journal:  JAMA       Date:  2009-06-17       Impact factor: 56.272

5.  Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial.

Authors:  R Phillip Dellinger; Sean M Bagshaw; Massimo Antonelli; Debra M Foster; David J Klein; John C Marshall; Paul M Palevsky; Lawrence S Weisberg; Christa A Schorr; Stephen Trzeciak; Paul M Walker
Journal:  JAMA       Date:  2018-10-09       Impact factor: 56.272

6.  Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.

Authors:  Steven M Opal; Pierre-Francois Laterre; Bruno Francois; Steven P LaRosa; Derek C Angus; Jean-Paul Mira; Xavier Wittebole; Thierry Dugernier; Dominique Perrotin; Mark Tidswell; Luis Jauregui; Kenneth Krell; Jan Pachl; Takeshi Takahashi; Claus Peckelsen; Edward Cordasco; Chia-Sheng Chang; Sandra Oeyen; Naoki Aikawa; Tatsuya Maruyama; Roland Schein; Andre C Kalil; Marc Van Nuffelen; Melvyn Lynn; Daniel P Rossignol; Jogadish Gogate; Mary B Roberts; Janice L Wheeler; Jean-Louis Vincent
Journal:  JAMA       Date:  2013-03-20       Impact factor: 56.272

7.  Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial.

Authors:  Didier M Payen; Joelle Guilhot; Yoann Launey; Anne Claire Lukaszewicz; Mahmoud Kaaki; Benoit Veber; Julien Pottecher; Olivier Joannes-Boyau; Laurent Martin-Lefevre; Matthieu Jabaudon; Olivier Mimoz; Rémi Coudroy; Martine Ferrandière; Eric Kipnis; Carlos Vela; Stéphanie Chevallier; Jihad Mallat; René Robert
Journal:  Intensive Care Med       Date:  2015-04-11       Impact factor: 17.440

8.  Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial.

Authors:  D J Klein; D Foster; P M Walker; S M Bagshaw; H Mekonnen; M Antonelli
Journal:  Intensive Care Med       Date:  2018-11-23       Impact factor: 17.440
  8 in total
  3 in total

1.  Focus on sepsis.

Authors:  Morten Hylander Møller; Waleed Alhazzani; Manu Shankar-Hari
Journal:  Intensive Care Med       Date:  2019-07-02       Impact factor: 17.440

Review 2.  The Rationale and Current Status of Endotoxin Adsorption in the Treatment of Septic Shock.

Authors:  Jakub Śmiechowicz
Journal:  J Clin Med       Date:  2022-01-26       Impact factor: 4.241

3.  Application of oXiris-continuous hemofiltration adsorption in patients with sepsis and septic shock: A single-centre experience in China.

Authors:  Yanyan Zhou; Chenfang Wu; Lin Ouyang; Ying Peng; Dingming Zhong; Xiaohong Xiang; Jinxiu Li
Journal:  Front Public Health       Date:  2022-09-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.